$0.34
+0.00 (+1.44%)
Open$0.34
Previous Close$0.33
Day High$0.35
Day Low$0.33
52W High$1.58
52W Low$0.30
Volume—
Avg Volume3.78M
Market Cap63.49M
P/E Ratio—
EPS$-0.19
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+6,624.6% upside
Current
$0.34
$0.34
Target
$22.81
$22.81
$15.42
$22.81 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 173.91M | 154.07M | 36.22M |
| Net Income | -22,665,767 | -18,071,571 | -2,507,722 |
| Profit Margin | -13.0% | -12.4% | -6.9% |
| EBITDA | -12,989,300 | -10,931,816 | -3,086,652 |
| Free Cash Flow | — | — | -2,753,402 |
| Rev Growth | +12.9% | +12.9% | +20.2% |
| Debt/Equity | 9.81 | 9.81 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |